No versions for patented drugs

Bs_logoImage
Joe C Mathew New Delhi
Last Updated : Jan 29 2013 | 12:47 AM IST

The move is important as it allows multinational drug firms to launch their patent-protected medicines without fear of infringement by domestic drug makers.

Leading drug firm Cipla had recently launched a low-cost version of cancer drug erlotinib, challenging the patent enjoyed by Swiss drug firm Roche on the medicine in India. The matter is under litigation after Roche dragged Cipla to the Delhi High Court alleging "patent infringement".

Multinational drug firms have welcomed the DCGI move. However, domestic players termed it "unwarranted" and without a legal basis.

"The laws governing drug regulation (Drugs and Cosmetics Act, 1940) do not provide for any linkage between patent status and regulatory approvals," they claimed.

"Patent linkage is the practice that creates a link between the patent status of a product and the application for a marketing authorisation. It prevents registration and authorisation of generic medicines until the expiry of the patent and considerably delays generic market entry," said DG Shah, secretary general, Indian Pharmaceutical Alliance.

"The decision was taken at my level as we need to reassure the industry that patents are honoured in India. I have asked drug companies to provide the details of the patents granted for their new medicines. Whenever a second application seeking marketing approval for the same medicine comes, we will pass on the details to the patent office for an expert opinion," DCGI Surinder Singh said.

Singh added that the authority would initiate formal discussions will all stakeholders, including the domestic pharma industry, before finalising the formal guidelines.

You’ve hit your limit of 5 free articles this month.
Subscribe now for unlimited access.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 27 2008 | 12:00 AM IST

4 out of 5 articles left

Subscribe to read without limits
Subscribe Now